Background: Treatment with cyclooxygenase-2 (COX-2) specific inhibitors may lead to adverse cardiovascular (CV) events. Objective: Determine relative risk (RR) of acute MI (AMI) or stroke associated with the COX-2 specific inhibitors celecoxib and rofecoxib, and nonspecific NSAIDs in treated hypertensive patients with osteoarthritis (OA) and/or rheumatoid arthritis (RA) in a large New England healthcare claims database. Methods: Population based retrospective analysis of >3 million patients aged >18 years enrolled in a private medical insurance plan in the New England region of the US, from January 1, 1999 -June 30, 2001 . Enrollment, medical claims data and pharmacy claim records were computer linked. NSAID and COX-2 specific users were identified using NDC codes. Outcomes of interest were identified by ICD-9-CM codes 410-414 (AMI) or 430-436 (stroke). Sub-group analysis included prostaglandin-mediated antihypertensives (ACEI, ARB, β-blocker). The incidence of CV events was estimated using Cox proportional hazard time-to-event models adjusted for CV risk factors. Results: RR for CV events with rofecoxib vs nonusers of NSAIDs was 2.45. No differences in RR were noted for celecoxib vs NSAIDS (p = 0.40) or nonusers (p = 0.06) and NSAIDs vs non-users (p = 0.59).
Conclusions:
Rofecoxib significantly increases risk of AMI or stroke in treated hypertensive patients with OA or RA compared with nonusers. Patients receiving celecoxib, nonspecific NSAIDs, ACEI, ARB or β-blockers are at no enhanced risk.
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